Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Simple item page
dc.contributor.affiliationCenter for AIDS Research, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
dc.contributor.affiliationCentre de Prise en Charge, de Recherche et de Formation, Abidjan, Côte d'Ivoire.
dc.contributor.affiliationCentre de Traitement Ambulatoire, Brazzaville, Republic of the Congo.
dc.contributor.affiliationNewlands Clinic, Harare, Zimbabwe.
dc.contributor.affiliationLighthouse Trust, Lilongwe, Malawi.
dc.contributor.affiliationInfectious Diseases Institute, Makerere University, Kampala, Uganda.
dc.contributor.affiliationDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
dc.contributor.affiliationCentre de Traitement Ambulatoire, Pointe Noire, Republic of the Congo.
dc.contributor.affiliationKwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa.
dc.contributor.affiliationInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
dc.contributor.affiliationInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
dc.contributor.affiliationAIDS Healthcare Foundation Uganda Cares, Masaka, Uganda.
dc.contributor.affiliationCentre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
dc.contributor.affiliationPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
dc.contributor.affiliationPublic Health Department, Regional Referral Hospital, Masaka, Uganda.
dc.contributor.affiliationCentre National de Transfusion Sanguine, Abidjan, Côte d'Ivoire.
dc.contributor.affiliationCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
dc.contributor.affiliationHôpital Jamot, Yaoundé and Regional Hospital, Limbé, Cameroon.
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
dc.contributor.affiliationFaculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
dc.contributor.affiliationCIDRZ
dc.contributor.affiliationCentre for Infectious Disease Research in Zambia (CIDRZ)
dc.contributor.authorLoosli T
dc.contributor.authorMoore CB
dc.contributor.authorBuzaalirwa L
dc.contributor.authorByakwaga H
dc.contributor.authorÇelikağ İ
dc.contributor.authorChimbetete C
dc.contributor.authorEbasone PV
dc.contributor.authorGiandhari J
dc.contributor.authorHan N
dc.contributor.authorHuwa J
dc.contributor.authorKasozi C
dc.contributor.authorMafoua A
dc.contributor.authorMessou E
dc.contributor.authorMinga A
dc.contributor.authorMuula G
dc.contributor.authorMuyindike W
dc.contributor.authorNdala ACM
dc.contributor.authorSauermann M
dc.contributor.authorSemeere A
dc.contributor.authorSingh L
dc.contributor.authorKouyos RD
dc.contributor.authorLessells R
dc.contributor.authorEgger M
dc.date.accessioned2025-07-10T11:06:29Z
dc.date.issued2025-May-20
dc.description.abstractDolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
dc.identifier.doi10.1093/cid/ciaf204
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/10841
dc.identifier.uri.pubmedhttps://pubmed.ncbi.nlm.nih.gov/40391923/
dc.sourceClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.titleDrug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

Files

Collections

Published